Vijaya Diagnostic Centre Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - Management discusses ample cash reserves (net surplus cash of INR 260 crores as of December 31, 2025), indicating sufficient liquidity. - Capital expenditure for FY '27 is estimated between INR 100-120 crores, expected to be funded from existing resources. - M&A is mentioned as an option if a suitable opportunity arises, but no active fundraising plans are disclosed for such activities. - Expansion is mainly planned to be organic with a focus on operational bandwidth and stabilization rather than immediate capital raising. Overall, there is no indication of imminent fundraising through debt or equity based on the February 13, 2026, earnings call transcript.

- FY '26 capex outlay utilized: INR 159 crores (including replacement capex). - FY '27 estimated capex plan for new centers: INR 100-120 crores. - Expansion plans for FY '27: 4-5 new hubs and 10-12 spokes. - FY '28 and '29 to see a balanced mix of hubs and spokes for optimal growth. - Focus on stabilizing current hubs before adding more, driven by operational bandwidth. - Investments ongoing in talent acquisition and digital/IT initiatives including high-end CRM, logistics app, cloud migration. - No immediate constraints on capital but strategic pacing due to operational challenges, not margin impact. - M&A remains an option subject to finding the right B2C asset at reasonable valuation; no current active deals.

- Expecting to surpass Q4 revenue growth guidance of 15%, despite a non-flu season and limited seasonality (Page 14). - Wellness segment revenue typically increases in Q4, especially post mid-February to March-end, driven by corporate packages and health checkups (Page 14). - FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). - Hub and spoke expansions ongoing: FY '27 to see 4-5 hubs and 10-12 spokes; FY '28-29 to have a balanced mix of hubs and spokes (Page 6). - Mature hubs (e.g., Hyderabad) continue organic volume growth of 10-15% (Page 6). - New geographies like West Bengal and Bangalore hubs have broken even early, indicating faster ramp-up and strong demand (Pages 8-13). - Expect ~2-4% volume growth in some mature hubs; Hyderabad cluster growing ~15% (Page 6). - Overall growth driven by integrated radiology and pathology services and network expansion across regions (Pages 3-5).

- Q4 FY26 expected to surpass 15% revenue growth guidance despite non-flu season and low seasonality (Siva Rama Raju). - Wellness segment revenue expected to pick up from mid-February to March, increasing its share in Q4 revenue. - Hub and spoke expansion planned with 4-5 new hubs and 10-12 spokes in FY27, with an optimal mix in FY28-29, supporting growth. - New hubs breaking even faster than anticipated (within 3-12 months), indicating quicker ramp-up and margin improvements. - Steady improvement in EBITDA margins, reported 41.9% in Q3 FY26, with guidance to maintain around 40%. - PAT margin around 21% for Q3 and 9-month periods, with potential for improvement as mature hubs stabilize. - Margin expansion driven by operational leverage from hub-spoke model and tele-radiology system enhancing profitability. - Capex in FY27 estimated INR 100-120 crores to support growth without major cost impact. - No explicit EPS guidance shared; implied growth from revenue and margin expansion trends.

The provided transcript of Vijaya Diagnostic Centre Limited's Q3 FY26 earnings call does not explicitly mention details about the current or expected order book or pending orders. Key points discussed relate to: - Hub and spoke expansion plans for FY27 (4-5 hubs and 10-12 spokes) and beyond. - Focus on operational stability and organic growth in existing and new geographies. - No direct mention of pending orders or an order backlog. - Discussion centers mainly on network expansion, revenue growth, margin guidance, and segment-wise performance. Therefore, information about order book or pending orders is not disclosed or available in the transcript.